Revenue: As of FY2026 Q2, the actual value is USD 898 K, missing the estimate of USD 2.234 M.

EPS: As of FY2026 Q2, the actual value is USD -1.01, beating the estimate of USD -1.1029.

EBIT: As of FY2026 Q2, the actual value is USD -42.73 M.

Financial Results for the Quarter and Six Months Ended June 30, 2026

Collaboration Revenue

• For the second quarter of 2026, Entrada Therapeutics, Inc. reported collaboration revenue of $898 thousand, a decrease from $1,950 thousand for the same period in 2025.
• For the six months ended June 30, 2026, collaboration revenue was $1,773 thousand, compared to $22,508 thousand for the same period in 2025.

Operating Expenses

• Research and Development (R&D) Expenses: R&D expenses were $35,369 thousand for the second quarter of 2026, down from $37,877 thousand in the prior year period, primarily due to lower personnel and facility costs, partially offset by additional expenses for the Company’s Duchenne muscular dystrophy (DMD) programs.
• For the six months ended June 30, 2026, R&D expenses were $68,423 thousand, compared to $69,951 thousand in the prior year period.
• General and Administrative (G&A) Expenses: G&A expenses totaled $10,492 thousand for the second quarter of 2026, a slight decrease from $10,922 thousand for the same period in 2025, primarily driven by lower professional services costs.
• For the six months ended June 30, 2026, G&A expenses were $20,616 thousand, compared to $21,196 thousand in the prior year period.
• Total Operating Expenses: Total operating expenses for the second quarter of 2026 were $45,861 thousand, down from $48,799 thousand in the second quarter of 2025.
• For the six months ended June 30, 2026, total operating expenses were $89,039 thousand, compared to $91,147 thousand in the prior year period.

Loss from Operations

• Loss from operations was -$44,963 thousand for the second quarter of 2026, an improvement from -$46,849 thousand for the same period in 2025.
• For the six months ended June 30, 2026, loss from operations was -$87,266 thousand, compared to -$68,639 thousand in the prior year period.

Interest and Other Income

• Interest and other income was $2,235 thousand for the second quarter of 2026, compared to $3,924 thousand for the same period in 2025.
• For the six months ended June 30, 2026, interest and other income was $4,859 thousand, compared to $8,365 thousand in the prior year period.

Net Loss

• Entrada Therapeutics, Inc. reported a net loss of -$42,763 thousand for the second quarter of 2026, compared to a net loss of -$43,103 thousand for the same period in 2025.
• For the six months ended June 30, 2026, the net loss was -$82,480 thousand, compared to -$60,452 thousand in the prior year period.

Cash Position

• Cash, cash equivalents, and marketable securities were $223,005 thousand as of June 30, 2026, a decrease from $295,698 thousand as of December 31, 2025, primarily driven by cash used to fund operations.

Balance Sheet Data (as of June 30, 2026)

• Total Assets: $298,877 thousand.
• Total Liabilities: $65,466 thousand.
• Total Stockholders’ Equity: $233,411 thousand.

Operational Metrics and Outlook

Entrada Therapeutics, Inc. anticipates several clinical data readouts, including ELEVATE-45-201 Cohort 1 data in October 2026 and ELEVATE-44-201 Cohort 1 open-label period data by year-end 2026, with ELEVATE-44-201 Cohort 2 data expected in the first quarter of 2027. Additionally, Vertex is projected to release VX-670 Phase ¹⁄₂ data in myotonic dystrophy type 1 (DM1) in the second half of 2026, and Entrada Therapeutics, Inc. plans to announce a second clinical candidate in ocular disease during the same period. Based on current operating plans, the Company expects its cash, cash equivalents, and marketable securities as of June 30, 2026, to fund operations into the third quarter of 2027.